Biotech entity
STAT News is most often covered alongside AMR Action Fund, which appears in 1 of these 2 stories. Across a 163-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.6 for the same window.
Last mentioned: 4d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
STAT News is most often covered alongside AMR Action Fund, which appears in 1 of these 2 stories. Across a 163-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.6 for the same window. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. At 7, the average consequence score sits above the same-window beat average of 6.1. This profile follows 2 Biotech stories mentioning STAT News across the period from March 10, 2026 to August 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 539 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering STAT News. Shared-story counts are live from our verified record — not editorial picks.
Hartford Courant reports Trump picks Overton
The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
STAT Analysis Released
Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.
Small Biotech Crisis
A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.
Market Exit Acceleration
Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.
Baseline Period
Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.
Biotech and pharma investors and executives face a potentially new FDA commissioner with no public drug-review track record. If Dr. Heidi Overton is confirmed, her priorities could reshape clinical trial standards, accelerated approval pathways, and review timelines. Early signals from the White House and confirmation hearings will matter most.
Source: abc7news.com · STAT News
A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.
STAT News is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
